Enter your keyword

Efficiently Creating Value with Innovative Science

Press Releases

Date Title and Summary Additional Formats
Toggle Summary MATEON PROVIDES CORPORATE UPDATE AND ANNOUNCES THIRD QUARTER 2020 FINANCIAL RESULTS
AGOURA HILLS, Calif. , Nov. 16, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB: MATN) today announced financial results for the third quarter ended September 30, 2020 (“Q3 2020”), as well as an update on its therapeutic development initiatives, including those
View HTML
Toggle Summary MATEON THERAPEUTICS AND WINDLAS BIOTECH ENTER INTO DEFINITIVE AGREEMENT TO COMMERCIALZE ARTIVEDA™ AGAINST COVID-19
AGOURA HILLS, Calif. , Nov. 11, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, announced today an agreement with Windlas Biotech Pvt. Ltd. of India (Windlas) to commercialize ARTIVeda ™ . ARTIVeda ™ is Mateon’s lead ethnobiology drug against
View HTML
Toggle Summary MATEON’S C001- A GLOBAL PHASE 2 STUDY FOR OT-101 AGAINST COVID-19- RECEIVED CLEARANCE FOR PATIENT ENROLLMENT
AGOURA HILLS, Calif. , Nov. 04, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB:MATN) announced today the receipt of approval from Instituto Nacional de Salud (INS), the regulatory agency of Peru , to initiate the Company’s C001- Phase 2 clinical trial of
View HTML
Toggle Summary MATEON TO HOST VIRTUAL SYMPOSIUM ADDRESSING COVID-19 ON NOVEMBER 11, 2020
“Advancing Ayurveda Through Ethnobiology Drug Development” Topics Include Mateon’s ARTIShield ™ for the Treatment of COVID-19 and COVID-19/Influenza Coinfection AGOURA HILLS, Calif. , Nov. 02, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB: MATN) today
View HTML
Toggle Summary MATEON ADVISOR DR. SUHAS KSHIRSAGAR WILL PRESENT AT DELHI UNIVERSITY ON ARTISHIELD™ FOR IMPROVING SYMPTOMS FOR COVID-19
Dr. Kshirsagar will speak on ARTIShield™ at Delhi University on Oct 28, 2020 in his talk titled “Ayurveda concepts of Pandemic and Immunity” Dr. Kshirsagar is advisor to Mateon on its Ayurvedic product ARTIShield™ in a global clinical trial to treat COVID-19. AGOURA HILLS, Calif. , Oct.
View HTML
Toggle Summary MATEON’S PHASE 2 GLOBAL STUDY FOR OT-101/ TGF-β INHIBITOR AGAINST COVID-19 CLEARED FOR PATIENT ENROLLMENT IN ARGENTINA.
AGOURA HILLS, Calif. , Oct. 19, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB:MATN) announced today the receipt of approval from Republica Argentina – Poder Ejecutivo Nacional, the regulatory agency of Argentina, to initiate the Company’s Phase 2 clinical
View HTML
Toggle Summary MATEON TO PARTICIPATE IN MERIDIAN CLINICAL TRIALS SUMMIT
AGOURA HILLS, California , Oct. 14, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and COVID-19, today announced that Dr. Vuong Trieu , President and CEO of Mateon, will present clinical updates at Meridian
View HTML
Toggle Summary MATEON TO PARTICIPATE IN BIO INVESTOR FORUM DIGITAL
AGOURA HILLS, California , Oct. 12, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and COVID-19, today announced that Dr. Vuong Trieu , President and CEO of Mateon, will present a company overview and host
View HTML
Toggle Summary MATEON ANNOUNCES FIRST PATIENT ENROLLED IN ARTI-19: A MULTICENTER INTERVENTIONAL STUDY OF ARTISHIELD™ AGAINST COVID-19
TOP-LINE DATA ANTICIPATED IN FOURTH QUARTER 2020 AGOURA HILLS, California , Oct. 07, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and COVID-19, announced the first patient enrolled this week in its Phase IV study
View HTML
Toggle Summary MATEON THERAPEUTICS TO INITIATE COMMERCIALIZATION OF ARTISHIELD™.
AGOURA HILLS, Calif. , Oct. 05, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics “Mateon” (OTC.QB: MATN), a leading developer of TGF-β therapeutics for oncology and COVID-19, today announced that ArtiShield TM is now approved for manufacture and marketing by the Ministry of AYUSH (Ayurveda, Yoga and
View HTML